

Cure® Presents

The Factor

Healthcare Innovation Summit

November 11 - 13, 2025

Agenda

Tuesday, November 11, 2025

Time	Session
As Scheduled	CURE TOUR Experience New York's Premiere Innovation Campus
12:30PM - 2:30PM <i>12th Floor</i>	WORKSHOP How to Build a Winning Pitch Workshop SPEAKER Sarah Sutton, PhD, Founder and Chief Executive Officer, Endurance PR
2:30PM - 4:30PM <i>12th Floor</i>	WORKSHOP Business Model Fundamentals SPEAKER Mark Marino, Vice President of Growth Strategy, VentureWell

Wednesday, November 12, 2025

Time	Session
8:00AM - 9:00AM <i>2nd Floor</i>	Breakfast
9:00AM - 9:15AM <i>2nd Floor</i>	Welcome Remarks SPEAKER Seema Kumar, Chief Executive Officer of Cure
9:15AM - 9:45AM <i>2nd Floor</i>	State of Global Healthcare Innovation Landscape MODERATOR Susan Lee, Partner at Goodwin Proctor KEYNOTE PANELIST Robert Califf, MD, Former Commissioner, US Food and Drug Administration (FDA) Seema Kumar, Chief Executive Officer of Cure
9:45AM - 10:30AM <i>2nd Floor</i>	Disruptive Technologies: AI's potential MODERATOR Michelle Chen, PhD, Chief Executive Officer, Form Bio PANELISTS Najat Khan, PhD, Chief R&D Officer, Chief Commercial Officer, & Board Member at Recursion Mark Michalski, MD, Chief Information Officer at Deerfield Management Maria Luisa Pineda, PhD, Chief Executive Officer and Co-Founder at Envisagenics
10:30AM - 11:00AM <i>2nd Floor</i>	Networking Break

Wednesday, November 12, 2025

Time	Session
11:00AM - 11:25AM <i>2nd Floor</i>	Fireside Chat with Daymond John, Star of ABC's <i>Shark Tank</i> MODERATOR Seema Kumar, Chief Executive Officer of Cure SPEAKER Daymond John, Star of ABC's <i>Shark Tank</i>
11:25AM - 12:00PM <i>2nd Floor</i>	Longevity Unlocked: Innovating for a Healthy Future MODERATOR Jeremy Abbate, Vice President and Publisher at Scientific American PANELISTS Daymond John, Star of ABC's <i>Shark Tank</i> Zahi Fayad, PhD, The Lucy G. Moses Professor in Medical Imaging and Bioengineering and Founding Director of the BioMedical Engineering and Imaging Institute at Mount Sinai James Peyer, PhD, Chief Executive Officer and Founder of Cambrian Bio
12:00PM - 1:30PM <i>12th Floor</i>	Lunch

Wednesday, November 12, 2025

Time	Session
1:30PM - 2:15PM <i>2nd Floor</i>	Bullseye: Finding and Defining Your Market for Startup Growth MODERATOR Jennifer Hawks Bland , Chief Executive Officer of New York Bio PANELISTS Johanna Grossman, PhD , Head of Healthcare & Lifesciences, Capital Markets at New York Stock Exchange Greg Moss , Chief Business and Legal Officer, Corporate Secretary and Chief Compliance Officer of Evommune Valerie B. Palmieri , Chief Executive Officer of Momentum Consulting
2:15PM - 2:45PM <i>2nd Floor</i>	Capital Compass: Finding the Right Funding Source MODERATOR Brian Korb , Co-founder and Managing Partner of Astr Partners PANELISTS Sarah E. Millar, PhD , Director of the Black Family Stem Cell Institute, Chair of the Department of Stem Cell Biology and Regenerative Medicine, and Dean for Academic and Scientific Affairs in the Icahn School of Medicine at Mount Sinai Tanima Sinha , Director Life Science Product Development and Government Contracts at BDO Lynda Stuart, MD, PhD , Chief Executive Officer of Fund for Science & Technology

Wednesday, November 12, 2025

Time	Session
2:45PM - 3:30PM <i>2nd Floor</i>	From Data to Results: Building your Compelling Investment Case MODERATOR David Greenwald, PhD , Managing Director at Deerfield Management PANELISTS Aamir A. Rehman, EdD , Associate Professor of Professional Practice and Senior Fellow at the Richard Paul Richman Center for Business, Law, and Public Policy at Columbia University Jim Reddoch, PhD , Chief Scientific Officer & Executive Vice President of Investments at Royalty Pharma Sara Nayeem, MD , Executive Vice President, Investments at Enavate Sciences
3:30PM - 4:00PM <i>2nd Floor</i>	Networking Break

Wednesday, November 12, 2025

Time	Session
4:00PM - 4:45PM <i>2nd Floor</i>	Winning the Talent Game: The Secret Sauce to Human Capital MODERATOR Francиска Lucien , Managing Director of Health Equity at the Clinton Global Initiative PANELISTS Shalabh Gupta, MD , Founder, President, and Chief Executive Officer of Unicycive Christine Miller , Global Life Science Leader & Former President and Chief Executive Officer of Melinta Therapeutics Juliet Agranoff , Chief People Officer at Taiho Oncology
4:45PM -6:15PM <i>Roof</i>	Cure Innovation Reception

Thursday, November 13, 2025

Time	Session
8:00AM - 9:00AM <i>2nd Floor</i>	Breakfast
9:00AM - 9:30AM <i>2nd Floor</i>	The State of US Healthcare Investment KEYNOTE SPEAKER Jim Flynn , Managing Partner at Deerfield Management
9:30AM - 10:15AM <i>2nd Floor</i>	Breakthrough Innovation: Game Changing Trends in Healthcare MODERATOR David Ewing Duncan , Best-selling Author and Award-winning Journalist PANELISTS Mathai Mammen, MD, PhD , Chairman, Chief Executive Officer & President of Parabilis Medicines Robert C. Green, MD, MPH , Physician-Scientist, Professor of Medicine at Harvard Medical School Jana Jensen, PhD , Co-Founder and Chief Operating Officer at Excelsior Sciences

Thursday, November 13, 2025

Time	Session
10:15AM - 11:00AM <i>2nd Floor</i>	Novel Clinical Trial Designs for Greater Patient Engagement MODERATOR Holly Schachner, MD , Chief Medical Officer of Deerfield Discovery and Development at Deerfield Management PANELISTS Janice Chang , Chief Executive Officer, TransCelerate BioPharma Lisa R. Treviño, PhD , Director of Clinical Trial Research Services, DLH Corporation Crohn's & Colitis Foundation Name To Be Announced
11:00AM - 11:15AM <i>2nd Floor</i>	Networking Break
11:15AM - 12:00PM <i>2nd Floor</i>	Gateway to Growth: Navigating Strategic Alliances Across Borders MODERATOR Rafael Perez , Senior Investment Officer, Eastern US at Invest Qatar PANELISTS Mussaad Al-Razouki, MD , Operating Partner at Deerfield Management Viq Pervaaz, MS , Senior Vice President of Life Sciences & Healthcare at the New York City Economic Development Corporation Devyn Smith, PhD , Chief Executive Officer of Arbor Biotech Debra Yu, MD , Chief Operating Officer of Panacea

Thursday, November 13, 2025

Time	Session
12:00PM - 1:30PM <i>12th Floor</i>	Lunch
1:30PM - 2:00PM <i>2nd Floor</i>	INNOVATION SPOTLIGHT K-BioHealth Startup Pitches
2:00PM - 2:30PM <i>2nd Floor</i>	INNOVATION SPOTLIGHT Innovation Seeking US Partnerships
2:30PM - 3:15PM <i>2nd Floor</i>	Breakthroughs in Women's Health MODERATOR Daniella Foster , Senior Vice President and Global Head of Public Affairs, Market Access and Sustainability at Bayer PANELIST Michelle Chen , PhD, Chief Executive Officer of Form Bio Kristen Dahlgren , Founder & CEO of Cancer Vaccine Coalition Katy Brodsky Falco , Founder and Executive Director at Foundation for Women's Health
3:15PM - 3:45PM <i>2nd Floor</i>	Networking Break

Thursday, November 13, 2025

Time	Session
3:45PM - 4:30PM <i>2nd Floor</i>	FIRESIDE CHAT Beyond Approval: Winning at Reimbursement in Healthcare and Technology MODERATOR Crystal Kuntz , Senior Vice President, Health Policy & Research at Biotechnology Innovation Organization (BIO) PANELIST(S) Heath Naquin , Senior Vice President, Innovation and New Ventures at University City Science Center
4:30PM - 4:45PM <i>2nd Floor</i>	Closing Remarks SPEAKER Seema Kumar , Chief Executive Officer of Cure
5:00PM - 7:00PM <i>Roof</i>	Cure X Tickets to Biotech Reception

Speakers

Jeremy Abbate

Vice President & Publisher
Scientific American



Jeremy A. Abbate is the VP & Publisher of *Scientific American* and its related titles. He is responsible for developing and executing new media programs, brand extensions and collaborative ventures serving the international opinion leadership that turns to *Scientific American* for the best views of the future.

He appears regularly at conferences and events to facilitate high-level discussions on healthcare, innovative science and technology. He has spearheaded co-branded partnerships with several international organizations including TEDMED, CES, the Bill & Melinda Gates Foundation and The Carter Center. Working to bring important scientific ideas into a dynamic media environment, he has led projects serving some of the world's largest corporate organizations, including Colgate Palmolive, Johnson & Johnson, Procter & Gamble, Philips, Amgen, BMS and others.

His writing has appeared in *The Wall Street Journal*, *Forbes*, *Psychology Today* and other national publications. Abbate penned the forward to the popular medical travel guide, *Patients Beyond Borders*. He serves on several advisory committees in the life science and healthcare space.

Juliet Agranoff

Chief People Officer
Taiho Oncology



Juliet Agranoff joined Taiho Oncology, Inc. as Senior Vice President, People in March 2019. Over the past decade, Juliet has brought her experience to specialty pharmaceutical firms such as The Medicines Company and Melinta Therapeutics, where she served as Senior Vice President and Head of Human Resources. Prior to that, she honed her talents and helped lead organizational change at a number of larger organizations including Pfizer, General Electric, Avon Products and Morgan Stanley.

With an inclusive, collaborative and empowering leadership style, Juliet leads the People function department at Taiho, and values her role in contributing to the growth of the company through building a foundation of credibility and trust.

Mussaad M. Al-Razouki, MD

Operating Partner
Deerfield Management



Dr. Mussaad M. Al-Razouki is an Operating Partner at Deerfield Management. Dr. Razouki has over 20 years of experience in venture capital and private equity investment with a focus on healthcare and technology, from clinical practice and research to the management and financing of healthcare systems.

Dr. Razouki is former Chief Business Development Officer of the Kuwait Life Science Company (KLSC), a wholly owned subsidiary of the National Technology Enterprises Corporation, which is the technology transfer and venture capital arm of the world's first sovereign wealth fund, the Kuwait Investment Authority (KIA). During his time at KLSC, Dr. Razouki represented the KIA as Vice Chairman of the Arab Company for Drug Industries and Medical Appliances (ACDIMA) in Amman, Jordan; Chairman of Société Arabe Des Industries Pharmaceutiques (SAIPH) in Tunis, Tunisia; and Board Member of the Tassili Arab Pharmaceutical Company (TAPHCO) in Algiers, Algeria and the Arab Pharmaceutical Company in Khartoum, Sudan.

An active angel investor, Dr. Razouki was the first investor in London-based home healthcare company Cera Care; Dubai-based women's health company Nabta Health; and Kuwait-based home health company BaitCare.com.

Jennifer Hawks Bland

Chief Executive Officer
NewYorkBio



Jennifer Hawks Bland is the Chief Executive Officer of NewYorkBio, the leading advocate for New York State's life science community. During her tenure at the helm of the trade organization, Jennifer has navigated NewYorkBio's growth to match the development of the life sciences industry across New York, nationally, and globally.

Prior to joining NewYorkBio, Jennifer served as an Executive Director in the State and Federal Government Affairs & Policy groups at Merck for almost 10 years. She has also held government affairs positions at GlaxoSmithKline and the Consumer Healthcare Products Association (CHPA).

Proudly hailing from the state of Mississippi, Jennifer is an alumna of Mississippi State University, where she earned her bachelor's degree in political science. Jennifer earned her law degree from the University of Mississippi School of Law before becoming a member of both the District of Columbia and Mississippi Bar Associations. Prior to joining the life science industry, Jennifer previously served as an associate with the Jackson, MS law firm of Butler, Snow, O'Mara, Stevens, & Cannada, PLLC, where she focused on pharmaceutical products liability defense and worked in the office of the late U.S. Senator Thad Cochran, R-Miss.

Robert Califf, MD

Former Commissioner
FDA



Robert Califf, MD, MACC, is an Instructor in Medicine in the Division of Cardiology. Dr. Califf was the Commissioner of Food and Drugs in 2016-2017 and in 2022-2025. Prior to his time as Commissioner, he was Deputy Commissioner for Medical Products and Tobacco from February 2015 to February 2016. Between his stints at FDA he was Head of Medical Policy and Strategy at Verily Life Sciences and Google Health. Prior to joining the FDA, Dr. Califf was a professor of medicine and vice chancellor for clinical and translational research at Duke University. He also served as director of the Duke Translational Medicine Institute and founding director of the Duke Clinical Research Institute. A nationally and internationally recognized expert in cardiovascular medicine, health outcomes research, healthcare quality, and clinical research, Dr. Califf has led many landmark clinical trials and is one of the most frequently cited authors in biomedical science, with more than 1,200 publications in the peer-reviewed literature.

Janice Chang

Chief Executive Officer
TransCelerate BioPharma



Janice Chang is the Chief Executive Officer at TransCelerate and a longtime champion of the potential of clinical research to accelerate answers for patients.

Since her appointment as CEO in 2023, Janice has worked closely with TransCelerate's board of directors to identify and shape a new aspiration for the organization focused on driving the convergence of clinical research and clinical care. Under her leadership, TransCelerate has also extended its horizon for collaboration beyond the world of global biopharma companies to include other stakeholders across the R&D ecosystem.

Janice's ongoing responsibilities include defining organizational priorities and overseeing the delivery of active initiatives. With her trademark high energy, commitment and courage, Janice also leads TransCelerate's engagement with global health authorities, governmental agencies, academic research institutions, and industry consortia.

She has been involved with TransCelerate since its inception in 2012 and holds a dual degree from the University of Pennsylvania and The Wharton School.

Michelle Chen, PhD

Chief Executive Officer
Form Bio



Michelle Chen, Ph.D. is a biotech executive and industry leader with extensive experience in strategy, business and corporate development, M&A, investor relations, ventures, fundraising, and R&D. She currently serves as President, CEO and Board Member of Form Bio, the first spin-off from Colossal Biosciences, where she leads company's efforts to harness AI for genetic medicine design and genome engineering applications.

Prior to Form Bio, Michelle served as Chief Business Officer at Insilico Medicine, where she drove the company's growth by translating cutting-edge AI technologies into high-value drug discovery and platform partnerships—unlocking billions in potential revenue.

Throughout her career, Michelle has built a strong cross-functional track record spanning R&D, product management, operations, and commercial leadership. She has held key positions at Roche, Merck, BioMarin, and Agilent Technologies, and has also served as an advisor to venture capital firms and startups. Michelle has led new company formations, executed numerous M&A transactions across the U.S., Europe, and Asia, and helped deliver a five-fold increase in the market capitalization of a public company within three years.

David Ewing Duncan

Best-selling Author and
Award-Winning Journalist



David Ewing Duncan is a bestselling author and award-winning journalist with a beat that includes the life sciences, the biotech sector, AI and technology, politics and culture. His work appears in media that span print outlets and 12 books, published in 21 languages, as well as television and radio. His work has appeared in *Wired*, *The New York Times*, *Vanity Fair* and *The Atlantic* and *Scientific American*. He is a former producer and correspondent for ABC Nightline and 20/20 and for NPR's Morning Edition. He also served as the Chief Correspondent of NPR Talk's Tech Nation. In his latest book *Microland: The Future of Life on Earth (and why it's smaller than you think)* (LittleBrownUK and Harvard U Press 2024), he reports on the impact of climate change and human activity on the microbiome of Earth that connects all life. As an entrepreneur and researcher in personal and molecular health data, Duncan has co-founded three companies and served as the founding director of the Center for Life Science Policy at UC Berkeley. Winner of the AAAS Magazine Story of the Year in 2003, and has been nominated for a National Magazine Award three times.

Katy Brodsky Falco

Founder and Executive Director
Foundation for Women's Health



Katy Brodsky Falco is the Founder and Executive Director of the Foundation for Women's Health. Katy comes to this work through an equity lens, having worked in criminal justice reform for 20 years. After surviving both HELLP syndrome and breast cancer, Katy was horrified to learn about the long history of inequities in rigorous research of women's health. Seeing how clearly the public sector failed to close the gender equity gap in health for decades across both democratic and republican administrations, she created the Foundation for Women's Health as a private sector solution to not only equalize research funding for diseases across gender, but also across disease. Katy has built and managed non-profit research organizations for leading academic institutions for the past decade. She was the Executive Director of NYU School of Law's Criminal Justice Lab, and prior to this, she was Executive Director of Crime Lab New York, a criminal justice research organization based at University of Chicago. She was also Executive Director of Reentry Services at the NYC Department of Corrections and a staff attorney at Legal Aid Society in the Criminal Defense Division. Katy attended Harvard University for her BA and NYU School of Law for her JD.

Zahi A. Fayad, PhD

Founding Director of the BioMedical
Engineering and Imaging Institute
Mount Sinai



Zahi A. Fayad, PhD is the Lucy G. Moses Professor of Medical Imaging and Bioengineering and founding director of the BioMedical Engineering and Imaging Institute at Mount Sinai. A finalist in the XPRIZE Healthspan competition, his research brings together AI, imaging, and nanomedicine to advance precision medicine, with a focus on cardiovascular and immune-related diseases. He pioneered MRI vessel-wall imaging (CARADS), advanced PET imaging of vascular inflammation, and uncovered links between brain activity, inflammation, and cardiovascular risk. His work on HDL-based nanoparticles is moving toward clinical translation in cancer, autoimmune disease, and transplant rejection. Dr. Fayad also directs the Mount Sinai DigiTwin Project, an AI-driven platform for real-time, personalized health optimization.

Jim Flynn

Managing Partner
Deerfield Management



Jim Flynn is the Managing Partner of Deerfield. He joined Deerfield in 2000 and is responsible for the management of the Firm. Under his leadership, Deerfield has built deep healthcare information expertise through the Deerfield Institute; expanded its investment capabilities to include venture and private structured financings; established the Deerfield Foundation to contribute toward the health and welfare of disadvantaged children; created Deerfield Discovery and Development, LLC, which organizes Deerfield's discovery research efforts; and founded Cure, a healthcare innovation center at 345 Park Avenue South in New York City.

Before joining Deerfield, Jim was an analyst at Furman Selz, covering pharmaceutical and medical device companies. Prior to that, he served as Vice President of Corporate Development of Alpharma Inc., a pharmaceutical company, where his responsibilities included business development and strategic planning, and the management of licensing transactions. Jim began his career in healthcare investing at Kidder, Peabody & Co., where he ultimately served as a senior analyst covering the specialty pharmaceutical industry.

He is a member of the Board of Trustees of the New York Academy of Medicine and is a member of the University of Michigan Life Sciences Institute Leadership Council. Jim holds a B.S. in Cellular and Molecular Biology and Economics from the University of Michigan and a M.S. in Biotechnology from Johns Hopkins University.

Daniella Foster

Senior Vice President and Global Head of
Public Affairs, Market Access & Sustainability
Bayer



Daniella Foster is the Senior Vice President and Global Head of Public Affairs, Market Access and Sustainability for Bayer's Consumer Health Division. In this role, she is responsible for global public affairs and policy, and embedding sustainability into the divisional business model, including strategy and ambition development, stakeholder engagement, proactive issues management, digital integration, implementation and impact stewardship.

An integrity-driven leader, Foster has worked with billion-dollar brands and across private and public sectors, from Hilton and Mars to the United States White House, State Department and United Nations. She has a proven track record in driving strategy, change management, business integration and transformation across consumer goods, health, hospitality and government industries. In her nearly 20 years of experience, she's led corporate and government affairs, business turnarounds, ESG (environmental, social and corporate governance) and strategic partnerships.

Robert C. Green MD, MPH

Physician-Scientist and
Professor of Medicine
Harvard Medical School



Robert C. Green, MD, MPH is a physician-scientist and Professor of Medicine at Harvard Medical School who directs the Genomes2People Research Program at Mass General Brigham, Ariadne Labs, and the Broad Institute. His research has demonstrated the safety, feasibility, and clinical value of returning unanticipated genetic risk information - from research cohorts to population-scale implementation. Dr. Green led the first federally funded clinical trials of genomic sequencing in healthy adults (MedSeq), active-duty military personnel (MilSeq), and infants (BabySeq), establishing a foundation for genomic medicine across the lifespan. He also led the ACMG working group that created the first recommendations for returning incidental findings, producing the widely adopted “ACMG list” of actionable genes. He led efforts to return genomic results in large-scale cohorts such as the Framingham and Jackson Heart Studies, designed return-of-results programs for the Verily-Google Baseline Project and NIH All of Us Research Program, and co-authored the first GA4GH policy on returning genomic results in research, helping to set global standards. He now serves as principal contact and co-lead of BEACONS, the first nationwide newborn sequencing initiative in the US. Dr. Green has advanced real-world implementation as co-founder of the start-ups Genome Medical and Nurture Genomics, and has reached global audiences through his TED Talk (go.ted.com/robertcgreen) on childhood screening and lifelong genomic medicine.

Dave Greenwald, PhD

Managing Director
Deerfield Management



David Greenwald, PhD, is a Managing Director on the Public Structured Finance team. Dr. Greenwald joined the Firm in 2018 as Vice President, Business Development before transitioning to his current role in 2025. Prior to joining Deerfield, Dr. Greenwald was the Director of Business Development at Johns Hopkins Technology Ventures. He was a co-founder and Chief Executive Officer of Relay Technology Management, Inc. and a co-inventor of the Relay Innovation Engine software platform. After Relay was acquired by Decision Resources Group, Dr. Greenwald served as the Director of Client Solutions at Decision Resources Group. Before that, he was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD, where he worked on developing diagnostic devices for dengue fever. Dr. Greenwald was a Howard Hughes Medical Institute research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland, College Park and earned his PhD in Genetics from Tufts University.

Johanna Grossman, PhD

Head of Healthcare & Life Sciences
Capital Markets
NYSE Group



Johanna Grossman, PhD, is the Head of Healthcare & Life Sciences Capital Markets at NYSE Group, a part of Intercontinental Exchange, Inc. (NYSE: ICE). Johanna is responsible for attracting new listings from companies within the healthcare and life sciences industry. She advises companies, private equity and venture capital firms, investment bankers and other key stakeholders on the IPO landscape, NYSE initiatives and listing venue selection. Prior to joining the NYSE, Johanna was Head of Healthcare at GLG, where she was responsible for the strategic and operational leadership of the firm's healthcare practice in the U.S. In this role, Johanna led a team of content and client service professionals responsible for organizing live meetings and managing client diligence engagements across all sectors of healthcare. Johanna earned her PhD in Organic Chemistry at Yale University. She also holds a master's degree in Organic Chemistry from Yale University and a B.S. in Chemistry from Florida International University.

Shalabh Gupta, MD

Founder, President & Chief Executive Officer
Unicycive



Shalabh Gupta, MD, is the founder of Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategy role at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS Investment Bank; and as an equity researcher covering biotechnology companies at Rodman & Renshaw (currently HC Wainwright). Dr. Gupta previously served as a medical advisor to Synageva BioPharma Corporation and as an advisor to New York University (NYU) Langone Medical Center's Office of Technology Transfer. Dr. Gupta is also the founder and Chief Executive Officer of Globavir, which had licensed diagnostic technology from Stanford university, which was then partnered with global commercial diagnostic companies. Dr. Gupta is an advisor to the UCSF Innovation Center, a role he has held since 2020. Since 2012, and has also been an advisor to SPARK, Stanford University School of Medicine. Dr. Gupta previously served on the board of directors for the Beall Center for Innovation and Entrepreneurship at the University of California Irvine, Paul Merage School of Business.

Jana Jensen, PhD

Co-Founder & Chief Operating Officer
Excelsior Sciences



Jana Jensen, Ph.D., is co-founder and Chief Operating Officer of Excelsior Sciences, Inc., a company dedicated to ushering in the molecular industrial revolution by transforming small molecule chemistry.

Prior to founding Excelsior Sciences, Jana served as the Chief Operating Officer of Deerfield Discovery and Development (3DC), where she partnered with Chief Executive Officer Mike Foley to build the team, infrastructure and partnerships behind a new model for innovative drug discovery.

Jana is passionate about translating groundbreaking ideas into practical, scalable impact. Her expertise lies in guiding scientific innovation toward focused execution and operational success.

Before her role at 3DC, she was Vice President and Head of Business Operations at Covance, leading a 300-person global team supporting a 20,000-employee organization. There she drove long-term strategy planning, governance and internal communications.

Jana's earlier career spanned two decades in the biopharma industry, including scientific and leadership roles at Merck, Pfizer and Bristol-Myers Squibb. She began her career as a research scientist and advanced through project and portfolio management to executive operations leadership roles.

Daymond John

Star of ABC's **Shark Tank**



An entrepreneur in every sense of the word, **Daymond John** has come a long way from taking out a \$100,000 mortgage on his mother's house and moving his business operation into its basement. John is Chief Executive Officer and Founder of FUBU, a much-celebrated global lifestyle brand, and a pioneer in the fashion industry with billions in product sales world-wide. Former President Barack Obama appointed Daymond John a Presidential Ambassador for Global Entrepreneurship to harness his energy, ideas, and experience to help develop the next generation of entrepreneurs both at home and abroad.

Najat Khan, PhD

Chief R&D Officer, Chief Commercial
Officer, & Board Member
Recursion



Najat Khan, Ph.D., is an accomplished biopharma leader at the forefront of driving bold innovation to bring transformative therapies to patients. Building on a track record of integrating science, AI/ data science, and business leadership across both large pharma and emerging TechBio, she serves as Chief R&D Officer, Chief Commercial Officer, and Board Member at Recursion, where she is advancing an AI-native approach to discovering, developing, and delivering novel medicines to address unmet patient needs.

At Recursion, Dr. Khan has combined bold vision with disciplined leadership to advance value and impact. She has sharpened the company's portfolio and optimized resource allocation across its pipeline and operations – prioritizing and progressing multiple first-in-class and best-in-class clinical programs in oncology, rare disease, neuroscience, and inflammation & immunology, both internally and with partners such as Sanofi and Roche/Genentech.

Dr. Khan also helped lead Recursion's combination with Exscientia – the largest TechBio deal of 2024 – and has expanded the Recursion OS 2.0 platform into an end-to-end engine for drug discovery and development, spanning biology, chemistry, and ClinTech. She has helped build a world-class “bilingual” team fluent in both science and data science and engages deeply with analysts, investors, and other stakeholders to strengthen understanding of Recursion's model and shape broader conversations about the future of biopharma and TechBio.

Brian Korb

Co-Founder and Managing Partner
Astr Partners



Brian Korb is the Co-Founder and Managing Partner of astr partners, a boutique investor relations and advisory firm focused on the life sciences sector, founded in 2024.

Prior to founding astr partners, Brian spent three years at Oppenheimer & Co., where he served as both Head of Healthcare Corporate Access & Institutional Engagement and a Managing Director in Healthcare Investment Banking.

Earlier in his career, Brian played a key role in leading the sale of The Trout Group to Solebury Capital (a division of PNC Bank), subsequently becoming Co-Head of Life Sciences at Solebury Trout. Over his tenure at Trout and Solebury, he advised hundreds of life sciences companies, earning a reputation as a trusted partner in investor relations and capital markets strategy. Brian currently serves on the Business Advisory Board for Latitude Food Allergy Care.

He graduated magna cum laude from Tufts University with a B.A. in Psychology. An endurance athlete, Brian has completed more than ten marathons and is an IRONMAN finisher. He is also an active member of the Plandome Volunteer Fire Department and the National Eagle Scout Association. Brian lives in Manhasset with his wife and their two energetic children.

Seema Kumar

Chief Executive Officer
Cure



Seema Kumar joined Cure Experience in 2022 as the Chief Executive Officer. Prior to Cure, Ms. Kumar spent nearly 20 years at Johnson & Johnson in senior leadership roles, including most recently as the Global Head, Office of Innovation, Global Health and Scientific Engagement, and served on J&J's Innovation Strategy, Public health leadership and the COVID-19 vaccine steering committee, where she led the company's external affairs efforts and public education program on COVID and vaccine literacy. Before her tenure at J&J, Ms. Kumar was the Chief of Staff to Dr. Eric Lander and the Chief Communications Officer at the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research where she played a leadership role in the Human Genome Project. She also has held leadership positions at the U.S. National Institutes of Allergy and Infectious Diseases (NIAID), the National Institutes of Health, and Johns Hopkins School of Medicine. Ms. Kumar holds an M.S. in Science Journalism and Communications from the University of Maryland.

Susan Lee

Partner

Goodwin Proctor



Susan Lee is a partner in Goodwin's Life Sciences group and Life Sciences Regulatory & Compliance practice.

Susan advises innovative biologics and drug companies on FDA regulatory and compliance matters that arise in the development and commercialization of new products and indications. She applies her prior business experience in the life sciences industry to provide practical, risk-calibrated solutions. Susan has counseled clients across the spectrum of the industry, from early clinical-stage companies to established global players.

Susan's areas of expertise include FDA development pathways; clinical trial recruitment and compliance; launch preparation, including labeling negotiations, development of core promotional claims, provider and patient engagement strategies, and field training; companion diagnostics and digital health tools; and interactions with patients, health care practitioners, and payors.

Susan routinely collaborates with colleagues in related legal areas, such as health care, data privacy, intellectual property and antitrust, to provide holistic advice to clients. She draws on her broad expertise to provide strategic advice in the context of investigations, litigation, corporate transactions, and securities disclosures. Susan has extensive experience with FDA matters that arise in due diligence, SEC filings and press releases, licensing and collaboration agreements, and agreements with distributors, specialty pharmacies, CRO/CMOs, consultants and other key partners.

Francиска Lucien

Managing Director
Clinton Global Initiative



Francиска Lucien is a Managing Director at the Clinton Global Initiative (CGI), where she leads its health work. A strategic executive with 15+ years of experience, she specializes in scaling innovation and driving transformative initiatives in the health sector. Her expertise spans strategic leadership, operational excellence, and cross-sector partnership building. Francиска holds a Master of Arts from the George Washington University Elliott School of International Affairs and a Bachelor of Science from the Georgetown University Edmund A. Walsh School of Foreign Service.

Mark Marino

Vice President of Growth Strategy
VentureWell



Mark Marino leads VentureWell's growth strategy, including new business cultivation and portfolio expansion of individual, foundation, corporate, and government revenue. This is accomplished through integrated partnerships and development work tied closely with VentureWell's marketing, communications, and events. He also serves as principal investigator and project director for several VentureWell initiatives. Mark has over 20 years of experience in U.S. and global health organizations leading operations, business development, board governance, program development, and administration. He has a background in molecular biology and infectious disease diagnostics and received a B.A. in Zoology and Neuroscience from Miami University, Ohio, and an M.P.H. from the Johns Hopkins Bloomberg School of Public Health.

Mathai Mammen, MD, PhD

Chairman, Chief Executive Officer &
President

Parabilis Medicines



Mathai Mammen, MD, Ph.D., is Chairman, Chief Executive Officer, and President of Parabilis Medicines, a biopharmaceutical company pioneering therapies for previously undruggable protein targets in oncology.

Previously, Mathai served as Global Head of R&D and a member of the Executive Committee at Johnson & Johnson. There, he led and evolved one of the world's largest pharmaceutical R&D organizations and spearheaded the strategic integration of data science and AI across the portfolio. During his tenure, his team secured global approvals for nine medicines—including Tremfya™, Darzalex Faspro™, Carvykti™, Tecvayli™, and Spravato™—and achieved an unprecedented 90% success rate in Phase 2 to Phase 3 transitions. He also oversaw 40+ acquisitions and licenses, along with 350+ strategic partnerships that expanded J&J's portfolio and capabilities.

Before J&J, Mathai was SVP at Merck, contributing to the development of Keytruda™ and the discovery of elicitide, and earlier co-founded Theravance, Inc., where he led R&D toward five approved therapies including Breo™, Anoro™, and Trelegy™. In total, he has led the discovery/development of 17 approved medicines.

Mathai's leadership philosophy rejects incrementalism in favor of unique, high-efficacy science with meaningful global impact, regardless of difficulty. He builds cross-disciplinary teams that integrate scientific rigor, advanced analytics including AI, and strategic business insight to accelerate transformational innovation.

Mark Michalski, MD

Chief Information Officer
Deerfield Management



Mark Michalski, MD, is Chief Information Officer and joined the Firm in 2024. Mark is responsible for overseeing the expansion and launch of new software and AI enabled products and services and supporting related capabilities for portfolio companies. Dr. Michalski concurrently serves as Chief Executive Officer at Ascertain, a technology company specializing in AI-driven automation solutions for healthcare enterprises. Before this, Dr. Michalski led strategic business development for Amazon's healthcare and life sciences business units. He also served as Founding Executive Director of Mass General Brigham AI (formerly the Center for Clinical Data Science). Earlier in his career, Dr. Michalski served as President and Chief Medical Officer at Butterfly Network (NYSE: BFLY) and Chief Medical Officer at Hyperfine Research (NASDAQ: HYPR). Dr. Michalski holds a B.S. in Cybernetics from University of California, Los Angeles, a MD from Stanford University School of Medicine, and completed residency training at Yale New Haven Hospital. Dr. Michalski is certified by the American Board of Radiology and holds a medical license in New York State.

Sarah E. Millar, PhD

Director of the Black Family Stem Cell Institute, Chair of the Department of Stem Cell Biology and Regenerative Medicine, and Dean for Academic and Scientific Affairs in the Icahn School of Medicine Mount Sinai



Dr. Sarah E. Millar is Director of the Black Family Stem Cell Institute, Chair of the Department of Stem Cell Biology and Regenerative Medicine, and Dean for Academic and Scientific Affairs in the Icahn School of Medicine at Mount Sinai. She heads the research efforts in regenerative medicine and stem cells at Mount Sinai and oversees the medical school's educational and research programs.

Dr. Millar has made seminal discoveries on the mechanisms controlling development and regeneration of skin and hair. Her current research directions include investigating how stem cell activity is altered in skin aging; delineating the mechanisms that cause differences in the appearance, function, and disease-susceptibility of skin in different body regions; and deciphering the molecular and cellular basis for acute and long-term loss of smell in COVID-19 disease.

Dr. Millar is an Editorial Board member for Developmental Cell and Experimental Dermatology, a Deputy Editor for the Journal of Investigative Dermatology, and has served on numerous national and international grant review committees. She has received awards in recognition of her research, including an NIH MERIT Award and the William Montagna Lectureship Award of the Society for Investigative Dermatology. Dr. Millar currently serves as President-elect of the Society for Investigative Dermatology.

Christine Miller

Global Life Science Leader & Former
President and Chief Executive Officer
Melinta Therapeutics



Christine Ann Miller is a transformational pharmaceutical executive with more than 20 years of experience driving strategic growth and innovation. As President and Chief Executive Officer of Melinta Therapeutics, she led the company's remarkable transformation from pure-play antibiotics to a leader in hospital acute care, driving 85% revenue growth, securing multiple FDA approvals, expanding the portfolio through licensing and acquisitions, and achieving sustainable profitability. Guided by her "people first" philosophy, she built high-performing teams and advanced operational rigor that positioned the company for sustainable profitability and strategic acquisition by CorMedix in August 2025.

Previously, Ms. Miller served as Global Head of Portfolio at Sandoz, a \$10 billion Novartis division, where she directed portfolio transition toward specialty segments, built a \$3 billion pipeline, and launched 50+ products. She spent over a decade at Actavis (now part of AbbVie), leading product launches and acquisitions that expanded global footprint. She began her career at Merck as a Chemical Engineer.

Ms. Miller's board experience includes Iveric Bio, Inc. (NASDAQ: ISEE), where she chaired the Committee for Business Development & Strategy and served on R&D and Nominating & Corporate Governance Committees. During her tenure, the company completed positive Phase III studies, achieved FDA approval, and was acquired by Astellas Pharma for \$5.9B. She currently serves on the boards of Melinta Therapeutics, the Antimicrobials Working Group, and BioNJ, and is Advisory Board Chair of the Healthcare Businesswomen's Association.

Greg Moss

Chief Business and Legal Officer, Corporate
Secretary and Chief Compliance Officer
Evommune



Gregory S. Moss serves as Chief Business and Legal Officer, as well as Corporate Secretary and Chief Compliance Officer of Evommune. Prior to Evommune, Greg served as Executive Vice President, General Counsel, and Corporate Secretary, Chief Compliance Officer at Kadmon, a Sanofi Company, where he led legal, compliance, and business development operations, culminating in Kadmon's successful \$1.9 billion acquisition in 2021. Greg helped lead Kadmon's integration into Sanofi, with broad corporate oversight over legal, compliance, business development, alliance management, human resources, quality assurance, and CMC business functions. During his decade-long tenure at Kadmon, Greg served in various roles of increasing responsibility. He was a key strategic partner in financing activities, including the transition from a private to a public company, helping raise more than a billion dollars in debt and equity, and business development efforts, including the spin-off of its gene therapy platform, various international and domestic collaboration and license, co-promotion and distribution agreements, and joint ventures. Greg also helped establish, and then led, Kadmon's corporate governance, public company, and healthcare compliance programs. Prior to joining Kadmon in 2012, Greg served as a solicitor in the corporate risk department of a large Australian law firm and as an associate at a boutique law firm and hedge fund in New York, where he focused on complex litigation and event-driven outcomes.

Heath Naquin

Senior Vice President,
Innovation and New Ventures
University City Science Center



Heath Naquin serves as Senior Vice President of Innovation & New Ventures at the Science Center, where he leads strategy and execution across venture creation, commercialization, AI adoption and capital formation initiatives.

In this role, he led the creation of the Science Center's flagship Capital Readiness Program, leads the organization's government partnerships and funding portfolio, and the expansion of its innovation platform into new geographic and sector markets. His work focuses on accelerating commercialization in medtech, AI, and dual-use technologies while addressing systemic capital gaps facing emerging ventures.

Over his career, Heath has created and deployed more than \$200 million in global venture funds focused on science and technology innovation, and has served as Principal Investigator or Co-Principal Investigator on more than \$250 million in funding and contracts spanning federal, state, and international programs.

He has led or advised major national and international initiatives in technology transfer, venture development, and fund creation, including the NIH RADx External Commercial Partnerships team, the U.S. Department of State's Global Innovation in Science and Technology (GIST) initiative across more than 130 countries, and commercialization and innovation programs supported by the National Science Foundation and European Investment Fund.

Sara Nayeem, MD

Executive Vice President, Investments
Enavate Sciences



Sara Nayeem, MD is Executive Vice President, Investments at Enavate Sciences. She focuses on portfolio strategy and plays a key role in the origination, evaluation, and selection of Enavates' partner companies. Additionally, she supports our portfolio with capital formation, strategic and select operational decisions. Sara currently serves on the board of directors on Normunity and as a board observer for Aviceda Therapeutics and previously served as a board observer for BridgeBio Oncology Therapeutics.

Sara has 20 years of experience in biotech investing and advisory services. She most recently served as Partner at Avoro Ventures, a biopharma venture fund she helped launch in 2021. Previously she was a Partner at New Enterprise Associates, Inc. (NEA), where she spent 12 years as part of the biopharma investing group. Over her investing career, Sara has played a key diligence and management role in 28 investments, from which there have been 11 IPOs and 10 acquisitions with upfront payments exceeding \$16 billion. Prior to joining NEA, Sara was an investment associate at Merrill Lynch, and she started her career as an investment banking analyst at Morgan Stanley banking. Sara has conducted basic science research in mammalian cardiac development and clinical research in age-related macular degeneration. She serves on the board of No Patient Left Behind, on the Advisory Board for The Blavatnik Fund for Innovation at Yale, and on the Memorial Sloan Kettering Technology Development Fund Review Committee.

Valerie B. Palmieri

Chief Executive Officer
Momentum Consulting



Valerie B. Palmieri, CEO of Momentum Consulting, is an experienced executive leader of high growth disruptive Public and Private Biotech companies serving as Chairwoman, Board Member, CEO/President, Senior Executive and Consulting Principal with oversight for multiple locations, 1,000 + employees, including sales, marketing, customer retention, operations, research, compliance, quality assurance and finance. She has a specific focus in women's health and FemTech serving as an advisor and board member to various women's health and novel disruptive technology organizations.

Prior positions include Executive Chair of Aspira Women's Health, CEO/President of Aspira Women's Health, COO of Aspira Women's Health, CEO/President of Diagnocure, Senior Vice President of Operations at Laboratory Corporation of America and DIANON Systems, Inc.

Rafael Perez

Senior Investment Officer, Eastern US
Invest Qatar



Rafael Perez is a seasoned Foreign Direct Investment (FDI) and economic development professional with two decades of experience spanning in both the public and private sectors. He has a strong track record of driving job creation and fostering economic growth across global markets—from countries and states to regional ecosystems.

Prior to joining Invest Qatar, Rafael led strategic business attraction efforts for Puerto Rico, successfully securing investments in high-impact sectors such as technology, life sciences, and advanced manufacturing. Earlier in his career, he served with the Government of Canada in New York, promoting trade and investment across key industries including digital health, fintech, cleantech, and cybersecurity.

Rafael has delivered major greenfield investment projects that generated thousands of full-time jobs, partnering with Fortune 500 companies and high-growth startups alike. His extensive network includes top-tier investors—VCs, angel investors, private equity firms, family offices—as well as corporate site selection consultants across North America.

Driven by a passion for innovation, Rafael excels at connecting cutting-edge companies with regions poised to attract talent and support sustainable growth. He holds a degree in Marketing and International Business from Iona University, is fluent in English and Spanish, and is currently pursuing his Certified Economic Developer (CEcD) designation through the International Economic Development Council (IEDC).

Viq Pervaaz

Senior Vice President, Life Sciences & Healthcare
**New York City Economic Development
Corporation**



Viq Pervaaz, MS, is the Senior Vice President, Life Sciences & Healthcare at the New York City Economic Development Corporation (NYCEDC). Pervaaz spearheads the LifeSci NYC initiative, a more than \$1 billion project to create jobs and establish New York City as a global leader in life sciences. Bringing extensive leadership in global market expansion, corporate strategy, and financial governance, Pervaaz's diverse background includes guiding strategic acquisitions, driving organizational transformation, and pioneering health equity and sustainability. Prior to joining NYCEDC, he held executive level roles in the biopharma, clinical, and consulting industries. He holds a pharmacy degree from Rutgers University College of Pharmacy, an master of science degree in management from MIT Sloan, and he completed an AMP at Harvard Business School.

James Peyer, PhD

Chief Executive Officer and Founder
Cambrian Bio



James Peyer, PhD, is the Chief Executive Officer and Founder of Cambrian Bio. Fascinated with the biology of aging since he was a teenager, James has spent his life pursuing ways to translate laboratory breakthroughs in geroscience into medicines that can treat and ultimately prevent today's most debilitating chronic disease. He is credited for creating the modern strategy for building companies around geroscience. He has founded and led over 20 startups, with multiple drugs now in human clinical trials. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. He earned his PhD at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.

Maria Luisa Pineda, PhD

Co-Founder & Chief Executive Officer
Envisagenics



Dr. Maria Luisa Pineda started as a high school Intel International Science Fair winner. For her undergraduate studies, Dr. Pineda was awarded an endowment of \$2 million dollars from the Goizueta Foundation and an NIH fellowship with the Minority Access to Research Careers (MARC U*STAR) program. Dr. Pineda received her Doctorate from the prestigious Cold Spring Harbor Laboratory School of Biological Sciences as an Arnold and Mabel Beckman graduate student and a William Randolph Hearst foundation scholar. After graduating, she acquired investment experience in technology and life-sciences startup companies at Canrock Ventures and Golden Seeds, LLC. Under her leadership, Envisagenics has received non-dilutive SBIR grants from the National Institutes of Health, raised capital from investors, won several prestigious artificial intelligence competitions, and formed multiple research collaboration partnerships with Biopharma.

Jim Reddoch, PhD

Chief Scientific Officer & Investments
Royalty Pharma



Jim Reddoch, PhD, has more than 25 years of experience in biopharma investing. As Royalty Pharma's CSO & EVP, Investments, he leverages his science background to identify trends and find new investment opportunities. He joined Royalty Pharma as EVP, Research, in 2008. Prior to joining Royalty Pharma, Jim led healthcare research at FBR Capital Markets. Previously, Jim was a biotechnology analyst at Bank of America and CIBC Capital Markets. Jim serves on the Boards of the Leukemia and Lymphoma Society (LLS) and the New York Academy of Sciences. He is on the MSK Leadership Council as well as the Review Board for MSK's Technology Development Investment Fund. He is co-Chairman of Life Science Cares New York and is on the National Board of Life Science Cares. Jim is on the President's Advisory Committee on Biology and Medicine at Brown University, as well as the President's Advisory Committee of Tyler Jacks' Break Through Cancer initiative. Jim is on Mass General Brigham's Bridging Academia and Industry Committee. Jim has a BA from Furman University, a PhD in biochemistry and molecular genetics from UAB, and was a postdoctoral fellow at Yale University.

Aamir A. Rehman, EdD

Associate Professor of Professional Practice and Senior Fellow at the Richard Paul Richman Center for Business, Law, and Public Policy
Columbia University



Aamir A. Rehman is an Associate Professor of Professional Practice and Senior Fellow at the Richard Paul Richman Center for Business, Law, and Public Policy at Columbia University. Since 2021, he has taught private equity courses to over 500 students in Columbia Business School's full-time MBA, Executive MBA, and Executive Education programs.

Dr. Rehman is Chair of Innate Capital Partners, which has invested as a Limited Partner over 10 funds and as a direct investor in over 15 companies. He serves on the boards of directors of multiple private equity related businesses, including both asset managers and portfolio companies. He is also an advisor to Fajr Capital, a private equity group of which he was a co-founder and managing director. Dr. Rehman has also advised family businesses on their sales to private equity groups.

In addition to his work in investment management, Dr. Rehman has served as a Senior Advisor to the United Nations Development Programme (UNDP) and a Consultant to the World Bank Group's Finance and Markets Global Practice. He is a trustee of Mercer County Community College and of the Rutgers Preparatory School.

Dr. Rehman is the author of the books *Dubai & Co.: Global Strategies for Doing Business in the Gulf States* (McGraw-Hill, 2007) and *Gulf Capital & Islamic Finance: The Rise of the New Global Players* (McGraw-Hill, 2009). He is also the author of numerous articles on finance and investments, capital flows, and the Gulf states.

Thomas P. Sakmar, MD

Richard M. and Isabel P. Furlaud Professor
The Rockefeller University



Thomas P. Sakmar, MD, is the Richard M. and Isabel P. Furlaud Professor at The Rockefeller University, where he heads the Laboratory of Chemical Biology and Signal Transduction. Dr. Sakmar uses interdisciplinary approaches to study how chemical signals are relayed from the outside to the inside of a cell – a process called signal transduction, which allows cells and organisms to sense their environments.

Dr. Sakmar received an A.B. in chemistry from the University of Chicago and his MD from Chicago's Pritzker School of Medicine. He carried out clinical training at the Massachusetts General Hospital and Harvard Medical School and conducted postdoctoral research with Nobel laureate H. Gobind Khorana at the Massachusetts Institute of Technology, studying DNA chemistry and gene synthesis. He has been an investigator of the Howard Hughes Medical Institute and a senior scholar of the Ellison Medical Foundation and has been a guest professor at the University of Copenhagen and at the Karolinska Institute, in Stockholm, which awarded him an honorary doctorate in 2020. Dr. Sakmar served as acting president of The Rockefeller University in 2002–2003.

Holly Schachner, MD

Chief Medical Officer,
Deerfield Discovery and Development
Deerfield Management



Holly Schachner, MD, is the Chief Medical Officer, Deerfield Discovery and Development and joined the Firm in 2023. Prior to Deerfield, Dr. Schachner was the Head of Clinical Development at North Sea Therapeutics, B.V. and she was the Chief Medical Officer at Double Rainbow Biosciences. Before these roles, she was the Senior Vice President, Clinical Development and Therapeutic Area and Innovative Trial Design Head for Myokardia-BMS and the Chief Medical Officer, Global Specialty Medicine for Allergan. Dr. Schachner also spent five years at Sanofi in various roles of increasing leadership, six years at Bayer Diabetes Care as Senior Director, Head of Global Medical Affairs, and five years at Pfizer. Prior to industry, Dr. Schachner received her training in pediatric endocrinology at Mount Sinai and led the Pediatric Diabetes program at Columbia University. She holds a B.A. in Psychology from the University Of Michigan and an M.D. from SUNY at Stony Brook School of Medicine.

Tanima Sinha

Director, Life Science Product Development
& Government Contracts
BDO USA



Tanima Sinha has over 25 years of combined experience in basic science research in HIV and other viral families, regulatory sciences and early & late-stage product development. For over 15 years, Tanima served as a Lead Interdisciplinary Scientist in the Influenza and Emerging Diseases Division (IEIDD) for the Biomedical Advanced Research and Development Authority (BARDA) within the Office of the Administration for Strategic Preparedness and Response (ASPR) at the US Department of Health and Human Services (DHHS). At BARDA, she was responsible for managing high value contracts with industry to further develop promising influenza (pre-pandemic and seasonal) and Zika vaccine candidates by providing technical and scientific direction along with regulatory and budgetary oversight. She also oversaw nonclinical development task orders for the SARS- CoV-2 response under Operation Warp Speed (OWS) and the 2016/2017 Zika virus response. Tanima led in establishing a new program for alternative routes of administration (e.g., microneedles, oral, intranasal) for vaccines and therapeutics leading to a new area of interest within BARDA/DRIVE.

Tanima joined BARDA in September 2008, taking with her over 5 years of regulatory science experience she gained as a Regulatory Health Project Manager at the US Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Division of Antiviral Products (DAVP).

Devyn Smith, PhD

Chief Executive Officer
Arbor Biotechnologies



Dr. Devyn Smith brings significant cell and gene therapy development and platform expertise from his 20+ year career. Devyn joined Arbor Biotechnologies as Chief Executive Officer on April 27, 2021 after concluding his role as Chief Operating Officer of Sigilon Therapeutics. Prior to Sigilon, Dr. Smith worked in a variety of roles at Pfizer Inc., including COO of the UK-based Neusentis Unit focused on discovering and developing cell therapies. He received his Ph.D. in Genetics from Harvard Medical School. He is an inventor on multiple patents and has published in leading scientific journals throughout his career. Dr. Smith is a board member and officer for ARM (Alliance for Regenerative Medicine), the cell and gene therapy industry group.

Lynda Stuart, MD, PhD

Chief Executive Officer

Fund for Science & Technology



Lynda Stuart, MD, PhD is a physician-scientist with over 20 years of experience in immunology, global health, and product development. She serves as President and Chief Executive Officer of Fund for Science and Technology (FFST), a new private foundation focused on advancing the fields of artificial intelligence, bioscience, and the environment to create lasting impact that benefits people and the planet. She was previously Executive Director of the Institute for Protein Design (IPD) at the University of Washington School of Medicine, Vice President of Infectious Disease at BioNTech, and Deputy Director Global Health at Bill & Melinda Gates Foundation, where she oversaw the preclinical development of vaccines and antibody therapies. Stuart is also an affiliate professor at Benaroya Research Institute at Virginia Mason, a member of the Scientific Advisory Council to the Coalition for Epidemic Preparedness and Innovation and a member of the Science and Technology Expert Group of the 100 Days Mission.

Sarah Sutton, PhD

Founder and Chief Executive Officer
Endurance PR



Sarah Sutton, Ph.D., is a communications strategist with 15 years of experience helping biotech founders and executives craft winning pitches and compelling narratives. She specializes in helping early-stage companies sharpen their investor presentations, refine their messaging, and communicate with clarity and confidence in high-stakes moments.

Her expertise spans investor deck development, storytelling frameworks, and media and speaker training, equipping scientists and entrepreneurs to present complex science in a way that resonates with funders, partners, and the broader life sciences ecosystem. Sarah has prepared leaders for investor pitches, board meetings, and high-profile media opportunities, guiding them to not only tell their story but also anticipate tough questions and respond with confidence.

She has held senior communications roles at Argot Partners, the Glover Park Group, Ten Bridge Communications, and the Broad Institute of MIT and Harvard, and has worked with companies across therapeutic areas and stages of growth. Sarah holds a Ph.D. in the History of Science from Brandeis University and a B.A. from Brown University.

Lisa Treviño, PhD

Director, Clinical Trial Research Services
DLH Corporation



Dr. Lisa R. Treviño is an accomplished clinical research operations executive and molecular biologist with a distinguished career leading large-scale research initiatives across the government contracting, pharmaceutical, and health system sectors. Renowned for her expertise in building and rapidly expanding clinical research portfolios, Dr. Treviño has managed operations for organizations delivering over 200 studies annually, and has successfully executed and overseen complex, multi-million-dollar, FDA-regulated and government-funded projects, including NIH, NIA, and NIAID contracts.

Dr. Treviño possesses deep subject matter expertise spanning infectious diseases (such as ZIKA, HIV, and COVID-19), oncology, liver disease, and metabolic disorders. She has a proven track record of negotiating major contracts with top biopharma companies and academic institutions, developing sustainable research infrastructures, and ensuring regulatory compliance and scientific excellence on every project under her leadership.

Driven by a passion for advancing biomedical research to benefit underserved and underrepresented populations, Dr. Treviño is a staunch advocate for community engagement and health equity. She has played a pivotal role in policy advocacy—testifying before legislative bodies to advance cancer biomarker access—as well as bridging infrastructure gaps for clinical trials in emerging and minority communities.

Debra Yu, MD

Chief Operating Officer
Panacea



Debra Yu, MD, currently serves as Chief Operating Officer and Partner at Panacea Venture. She has nearly 4 decades of experience as an investor, strategist, investment banker and business development executive. She also serves as a Board Member at MeiraGTx Holdings PLC (NASDAQ: MGTX), Ascentage Pharma (NASDAQ: AAPGV/HKG: 6855) and JW (Cayman) Therapeutics Co Ltd (HKG: 2126). Her prior roles include Founding President of Lianbio, Managing Director and Head of Cross Border Healthcare Investment Banking at China Renaissance Securities (U.S.), Managing Director of Labrador Advisors, and Team Leader for Pfizer Venture Investments. She has held other positions at Bay City Capital, Delphi Ventures, McKinsey and Morgan Stanley. She received a bachelor's degree with high honors in molecular biology from Princeton University and earned her medical degree from Harvard Medical School.

Cure® Membership

Some signals are only visible to innovators.

Those who catch it shape what comes next. That's why we've built a membership designed to help healthcare entrepreneurs cut through the noise, save time and accelerate what matters:

- **Masterclasses** on building healthcare businesses led by investors and experts
- **Exclusive access** to monthly webinars and office hours with top leaders
- **Curated connections** through 1:1 introductions to peers, mentors, and experts
- **In-person events** and startup showcases at 345 Park Avenue South
- **Continuous learning** via proprietary data, white papers, and deep-dive reports
- **A digital community**, your "LinkedIn for healthcare innovators"



Visit www.willcure.com/membership
or scan the QR code to learn more.